Aging and amyloid beta-induced oxidative DNA damage and mitochondrial dysfunction in Alzheimer's disease: Implications for early intervention and therapeutics

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1812, Issue 11, 2011, Pages 1359-1370

  Mao, Peizhong ^a   Reddy, P Hemachandra ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Amyloid ; Antioxidant; DNA repair; Oxidative stress; P53; Telomere

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-42]; DNA; GENOMIC DNA; HUPERZINE A; MITOCHONDRIAL DNA; PLACEBO; PROSTAGLANDIN SYNTHASE; PROTEIN P53; REACTIVE OXYGEN METABOLITE; TAU PROTEIN; TELOMERASE;

AGING; ALZHEIMER DISEASE; ANTIBODY TITER; BIOACCUMULATION; COMET ASSAY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA DAMAGE; DNA DETERMINATION; DNA REPAIR; DNA SEQUENCE; DRUG WITHDRAWAL; ENCEPHALITIS; ENZYME ACTIVITY; ENZYME INHIBITION; EXCISION REPAIR; GENOTOXICITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; LIFESTYLE; MITOCHONDRION; NERVE CELL NECROSIS; NONHUMAN; OXIDATIVE STRESS; POINT MUTATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REVIEW; SEQUENCE ANALYSIS; TELOMERE; TISSUE SECTION;

AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; DNA DAMAGE; HUMANS; MICE; MITOCHONDRIA; OXIDATION-REDUCTION; OXIDATIVE STRESS;

MUS MUSCULUS;

EID: 80052538857     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2011.08.005     Document Type: Review

References (174)

1. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 2001, 81:741-766.
2. Alzheimer's Association W., Thies W., Bleiler L. Alzheimer's disease facts and figures. Alzheimers Dement. 2011, 7(2011):208-244.
3. Mattson M.P. Pathways towards and away from Alzheimer's disease. Nature 2004, 430:631-639.
4. Swerdlow R.H., Khan S.M. The Alzheimer's disease mitochondrial cascade hypothesis: an update. Exp. Neurol. 2009, 218:308-315.
5. LaFerla F.M., Green K.N., Oddo S. Intracellular amyloid-beta in Alzheimer's disease. Nat. Rev. Neurosci. 2007, 8:499-509.
6. Reddy P.H., Beal M.F. Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends Mol. Med. 2008, 14:45-53.
7. Du H., Guo L., Yan S., Sosunov A.A., McKhann G.M., Yan S.S. Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:18670-18675.
8. Marques F.Z., Markus M.A., Morris B.J. The molecular basis of longevity, and clinical implications. Maturitas 2010, 65:87-91.
9. Shammas M.A. Telomeres, lifestyle, cancer, and aging. Curr. Opin. Clin. Nutr. Metab. Care 2011, 14:28-34.
10. Eisenberg D.T. An evolutionary review of human telomere biology: the thrifty telomere hypothesis and notes on potential adaptive paternal effects. Am. J. Hum. Biol. 2011, 23:149-167.
11. Sahin E., Depinho R.A. Linking functional decline of telomeres, mitochondria and stem cells during ageing. Nature 2010, 464:520-528.
12. Kenyon C. The plasticity of aging: insights from long-lived mutants. Cell 2005, 120:449-460.
13. Bishop N.A., Lu T., Yankner B.A. Neural mechanisms of ageing and cognitive decline. Nature 2010, 464:529-535.
14. Droge W., Schipper H.M. Oxidative stress and aberrant signaling in aging and cognitive decline. Aging Cell 2007, 6:361-370.
15. Halliwell B., Cross C.E. Oxygen-derived species: their relation to human disease and environmental stress. Environ. Health Perspect. 1994, 102(Suppl. 10):5-12.
16. Lin M.T., Beal M.F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006, 443:787-795.
17. Sahin E., Colla S., Liesa M., Moslehi J., Muller F.L., Guo M., Cooper M., Kotton D., Fabian A.J., Walkey C., Maser R.S., Tonon G., Foerster F., Xiong R., Wang Y.A., Shukla S.A., Jaskelioff M., Martin E.S., Heffernan T.P., Protopopov A., Ivanova E., Mahoney J.E., Kost-Alimova M., Perry S.R., Bronson R., Liao R., Mulligan R., Shirihai O.S., Chin L., DePinho R.A. Telomere dysfunction induces metabolic and mitochondrial compromise. Nature 2011, 470:359-365.
18. Finck B.N., Kelly D.P. PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J. Clin. Invest. 2006, 116:615-622.
19. Hamilton M.L., Guo Z., Fuller C.D., Van Remmen H., Ward W.F., Austad S.N., Troyer D.A., Thompson I., Richardson A. A reliable assessment of 8-oxo-2-deoxyguanosine levels in nuclear and mitochondrial DNA using the sodium iodide method to isolate DNA. Nucleic Acids Res. 2001, 29:2117-2126.
20. Sedelnikova O.A., Horikawa I., Zimonjic D.B., Popescu N.C., Bonner W.M., Barrett J.C. Senescing human cells and ageing mice accumulate DNA lesions with unrepairable double-strand breaks. Nat. Cell Biol. 2004, 6:168-170.
21. von Figura G., Hartmann D., Song Z., Rudolph K.L. Role of telomere dysfunction in aging and its detection by biomarkers. J. Mol. Med. 2009, 87:1165-1171.
22. Blackburn E.H. Structure and function of telomeres. Nature 1991, 350:569-573.
23. d'Adda di Fagagna F., Reaper P.M., Clay-Farrace L., Fiegler H., Carr P., Von Zglinicki T., Saretzki G., Carter N.P., Jackson S.P. A DNA damage checkpoint response in telomere-initiated senescence. Nature 2003, 426:194-198.
24. Gordon D.M., Santos J.H. The emerging role of telomerase reverse transcriptase in mitochondrial DNA metabolism. J. Nucleic Acids 2010, 2010:390791.
25. Campisi J. Cellular senescence as a tumor-suppressor mechanism. Trends Cell Biol. 2001, 11:S27-S31.
26. Batista L.F., Pech M.F., Zhong F.L., Nguyen H.N., Xie K.T., Zaug A.J., Crary S.M., Choi J., Sebastiano V., Cherry A., Giri N., Wernig M., Alter B.P., Cech T.R., Savage S.A., Reijo Pera R.A., Artandi S.E. Telomere shortening and loss of self-renewal in dyskeratosis congenita induced pluripotent stem cells. Nature 2011, 474:399-402.
27. Jiang H., Schiffer E., Song Z., Wang J., Zurbig P., Thedieck K., Moes S., Bantel H., Saal N., Jantos J., Brecht M., Jeno P., Hall M.N., Hager K., Manns M.P., Hecker H., Ganser A., Dohner K., Bartke A., Meissner C., Mischak H., Ju Z., Rudolph K.L. Proteins induced by telomere dysfunction and DNA damage represent biomarkers of human aging and disease. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:11299-11304.
28. Song Z., von Figura G., Liu Y., Kraus J.M., Torrice C., Dillon P., Rudolph-Watabe M., Ju Z., Kestler H.A., Sanoff H., Lenhard Rudolph K. Lifestyle impacts on the aging-associated expression of biomarkers of DNA damage and telomere dysfunction in human blood. Aging Cell 2010, 9:607-615.
29. Nalapareddy K., Jiang H., Guachalla Gutierrez L.M., Rudolph K.L. Determining the influence of telomere dysfunction and DNA damage on stem and progenitor cell aging: what markers can we use?. Exp. Gerontol. 2008, 43:998-1004.
30. Ferron S.R., Marques-Torrejon M.A., Mira H., Flores I., Taylor K., Blasco M.A., Farinas I. Telomere shortening in neural stem cells disrupts neuronal differentiation and neuritogenesis. J. Neurosci. 2009, 29:14394-14407.
31. Tedeschi A., Di Giovanni S. The non-apoptotic role of p53 in neuronal biology: enlightening the dark side of the moon. EMBO Rep. 2009, 10:576-583.
32. Horikawa K., Fujita, Harris C.C. p53 governs telomere regulation feedback too, via TRF2. Aging (Albany, N. Y.) 2011, 3:26-32.
33. Coppede F., Migliore L. DNA damage and repair in Alzheimer's disease. Curr. Alzheimer Res. 2009, 6:36-47.
34. Gredilla R., Bohr V.A., Stevnsner T. Mitochondrial DNA repair and association with aging-an update. Exp. Gerontol. 2010, 45:478-488.
35. Kisby G.E., Fry R.C., Lasarev M.R., Bammler T.K., Beyer R.P., Churchwell M., Doerge D.R., Meira L.B., Palmer V.S., Ramos-Crawford A.L., Ren X., Sullivan R.C., Kavanagh T.J., Samson L.D., Zarbl H., Spencer P.S. The cycad genotoxin MAM modulates brain cellular pathways involved in neurodegenerative disease and cancer in a DNA damage-linked manner. PLoS One 2011, 6:e20911.
36. d'Adda di Fagagna F. Living on a break: cellular senescence as a DNA-damage response. Nat. Rev. Cancer 2008, 8:512-522.
37. van der Lugt N.M., Domen J., Linders K., van Roon M., Robanus-Maandag E., te Riele H., van der Valk M., Deschamps J., Sofroniew M., van Lohuizen M. Posterior transformation, neurological abnormalities, and severe hematopoietic defects in mice with a targeted deletion of the bmi-1 proto-oncogene. Genes Dev. 1994, 8:757-769.
38. Liu J., Cao L., Chen J., Song S., Lee I.H., Quijano C., Liu H., Keyvanfar K., Chen H., Cao L.Y., Ahn B.H., Kumar N.G., Rovira I.I., Xu X.L., van Lohuizen M., Motoyama N., Deng C.X., Finkel T. Bmi1 regulates mitochondrial function and the DNA damage response pathway. Nature 2009, 459:387-392.
39. Mirra S.S., Heyman A., McKeel D., Sumi S.M., Crain B.J., Brownlee L.M., Vogel F.S., Hughes J.P., van Belle G., Berg L. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991, 41:479-486.
40. Selkoe D.J. Normal and abnormal biology of the beta-amyloid precursor protein. Annu. Rev. Neurosci. 1994, 17:489-517.
41. Troy C.M., Rabacchi S.A., Friedman W.J., Frappier T.F., Brown K., Shelanski M.L. Caspase-2 mediates neuronal cell death induced by beta-amyloid. J. Neurosci. 2000, 20:1386-1392.
42. Cleary J.P., Walsh D.M., Hofmeister J.J., Shankar G.M., Kuskowski M.A., Selkoe D.J., Ashe K.H. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat. Neurosci. 2005, 8:79-84.
43. Gouras G.K., Almeida C.G., Takahashi R.H. Intraneuronal Abeta accumulation and origin of plaques in Alzheimer's disease. Neurobiol. Aging 2005, 26:1235-1244.
44. Chong Y.H., Shin Y.J., Lee E.O., Kayed R., Glabe C.G., Tenner A.J. ERK1/2 activation mediates Abeta oligomer-induced neurotoxicity via caspase-3 activation and tau cleavage in rat organotypic hippocampal slice cultures. J. Biol. Chem. 2006, 281:20315-20325.
45. Bero A.W., Yan P., Roh J.H., Cirrito J.R., Stewart F.R., Raichle M.E., Lee J.M., Holtzman D.M. Neuronal activity regulates the regional vulnerability to amyloid-beta deposition. Nat. Neurosci. 2011, 14:750-756.
46. Calhoun M.E., Wiederhold K.H., Abramowski D., Phinney A.L., Probst A., Sturchler-Pierrat C., Staufenbiel M., Sommer B., Jucker M. Neuron loss in APP transgenic mice. Nature 1998, 395:755-756.
47. Radde R., Bolmont T., Kaeser S.A., Coomaraswamy J., Lindau D., Stoltze L., Calhoun M.E., Jaggi F., Wolburg H., Gengler S., Haass C., Ghetti B., Czech C., Holscher C., Mathews P.M., Jucker M. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. 2006, 7:940-946.
48. Rupp N.J., Wegenast-Braun B.M., Radde R., Calhoun M.E., Jucker M. Early onset amyloid lesions lead to severe neuritic abnormalities and local, but not global neuron loss in APPPS1 transgenic mice. Neurobiol. Aging 2010.
49. Yan P., Bero A.W., Cirrito J.R., Xiao Q., Hu X., Wang Y., Gonzales E., Holtzman D.M., Lee J.M. Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice. J. Neurosci. 2009, 29:10706-10714.
50. Geula C., Wu C.K., Saroff D., Lorenzo A., Yuan M., Yankner B.A. Aging renders the brain vulnerable to amyloid beta-protein neurotoxicity. Nat. Med. 1998, 4:827-831.
51. Shah P., Lal N., Leung E., Traul D.E., Gonzalo-Ruiz A., Geula C. Neuronal and axonal loss are selectively linked to fibrillar amyloid-{beta} within plaques of the aged primate cerebral cortex. Am. J. Pathol. 2010, 177:325-333.
52. Kang J., Lemaire H.G., Unterbeck A., Salbaum J.M., Masters C.L., Grzeschik K.H., Multhaup G., Beyreuther K., Muller-Hill B. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987, 325:733-736.
53. Hardy J. Has the amyloid cascade hypothesis for Alzheimer's disease been proved?. Curr. Alzheimer Res. 2006, 3:71-73.
54. Reddy P.H., Manczak M., Mao P., Calkins M.J., Reddy A.P., Shirendeb U. Amyloid-beta and mitochondria in aging and Alzheimer's disease: implications for synaptic damage and cognitive decline. J. Alzheimers Dis. 2010, 20(Suppl. 2):S499-S512.
55. Seubert P., Vigo-Pelfrey C., Esch F., Lee M., Dovey H., Davis D., Sinha S., Schlossmacher M., Whaley J., Swindlehurst C. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 1992, 359:325-327.
56. Suzuki N., Cheung T.T., Cai X.D., Odaka A., Otvos L., Eckman C., Golde T.E., Younkin S.G. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science 1994, 264:1336-1340.
57. Iwatsubo T., Odaka A., Suzuki N., Mizusawa H., Nukina N., Ihara Y. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 1994, 13:45-53.
58. Roher A.E., Lowenson J.D., Clarke S., Woods A.S., Cotter R.J., Gowing E., Ball M.J. Beta-amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 1993, 90:10836-10840.
59. Miller D.L., Papayannopoulos I.A., Styles J., Bobin S.A., Lin Y.Y., Biemann K., Iqbal K. Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease. Arch. Biochem. Biophys. 1993, 301:41-52.
60. Findeis M.A. The role of amyloid beta peptide 42 in Alzheimer's disease. Pharmacol. Ther. 2007, 116:266-286.
61. Tamaoka A., Odaka A., Ishibashi Y., Usami M., Sahara N., Suzuki N., Nukina N., Mizusawa H., Shoji S., Kanazawa I. APP717 missense mutation affects the ratio of amyloid beta protein species (A beta 1-42/43 and a beta 1-40) in familial Alzheimer's disease brain. J. Biol. Chem. 1994, 269:32721-32724.
62. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
63. Vassar R., Kovacs D.M., Yan R., Wong P.C. The beta-secretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potential. J. Neurosci. 2009, 29:12787-12794.
64. Tamagno E., Bardini P., Obbili A., Vitali A., Borghi R., Zaccheo D., Pronzato M.A., Danni O., Smith M.A., Perry G., Tabaton M. Oxidative stress increases expression and activity of BACE in NT2 neurons. Neurobiol. Dis. 2002, 10:279-288.
65. Guglielmotto M., Aragno M., Autelli R., Giliberto L., Novo E., Colombatto S., Danni O., Parola M., Smith M.A., Perry G., Tamagno E., Tabaton M. The up-regulation of BACE1 mediated by hypoxia and ischemic injury: role of oxidative stress and HIF1alpha. J. Neurochem. 2009, 108:1045-1056.
66. McGowan E., Pickford F., Kim J., Onstead L., Eriksen J., Yu C., Skipper L., Murphy M.P., Beard J., Das P., Jansen K., Delucia M., Lin W.L., Dolios G., Wang R., Eckman C.B., Dickson D.W., Hutton M., Hardy J., Golde T. Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron 2005, 47:191-199.
67. Ertekin-Taner N., Younkin L.H., Yager D.M., Parfitt F., Baker M.C., Asthana S., Hutton M.L., Younkin S.G., Graff-Radford N.R. Plasma amyloid beta protein is elevated in late-onset Alzheimer disease families. Neurology 2008, 70:596-606.
68. Blasko, Kemmler G., Jungwirth S., Wichart I., Krampla W., Weissgram S., Jellinger K., Tragl K.H., Fischer P. Plasma amyloid beta-42 independently predicts both late-onset depression and Alzheimer disease. Am. J. Geriatr. Psychiatry 2010, 18:973-982.
69. Aisen P.S., Andrieu S., Sampaio C., Carrillo M., Khachaturian Z.S., Dubois B., Feldman H.H., Petersen R.C., Siemers E., Doody R.S., Hendrix S.B., Grundman M., Schneider L.S., Schindler R.J., Salmon E., Potter W.Z., Thomas R.G., Salmon D., Donohue M., Bednar M.M., Touchon J., Vellas B. Report of the task force on designing clinical trials in early (predementia) AD. Neurology 2011, 76:280-286.
70. Vellas B., Black R., Thal L.J., Fox N.C., Daniels M., McLennan G., Tompkins C., Leibman C., Pomfret M., Grundman M. Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr. Alzheimer Res. 2009, 6:144-151. AN1792 (QS-21)-251 Study Team.
71. Boche D., Denham N., Holmes C., Nicoll J.A. Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis. Acta Neuropathol. 2010, 120:369-384.
72. Rinne J.O., Brooks D.J., Rossor M.N., Fox N.C., Bullock R., Klunk W.E., Mathis C.A., Blennow K., Barakos J., Okello A.A., Rodriguez Martinez de Liano S., Liu E., Koller M., Gregg K.M., Schenk D., Black R., Grundman M. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010, 9:363-372.
73. Iijima-Ando, Zhao L., Gatt A., Shenton C., Iijima K. A DNA damage-activated checkpoint kinase phosphorylates tau and enhances tau-induced neurodegeneration. Hum. Mol. Genet. 2010, 19:1930-1938.
74. Goedert M., Spillantini M.G., Jakes R., Rutherford D., Crowther R.A. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 1989, 3:519-526.
75. Zheng W.H., Bastianetto S., Mennicken F., Ma W., Kar S. Amyloid beta peptide induces tau phosphorylation and loss of cholinergic neurons in rat primary septal cultures. Neuroscience 2002, 115:201-211.
76. Huang H.C., Jiang Z.F. Accumulated amyloid-beta peptide and hyperphosphorylated tau protein: relationship and links in Alzheimer's disease. J. Alzheimers Dis. 2009, 16:15-27.
77. Ittner L.M., Ke Y.D., Delerue F., Bi M., Gladbach A., van Eersel J., Wolfing H., Chieng B.C., Christie M.J., Napier I.A., Eckert A., Staufenbiel M., Hardeman E., Gotz J. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 2010, 142:387-397.
78. Sievers S.A., Karanicolas J., Chang H.W., Zhao A., Jiang L., Zirafi O., Stevens J.T., Munch J., Baker D., Eisenberg D. Structure-based design of non-natural amino-acid inhibitors of amyloid fibril formation. Nature 2011, 475:96-100.
79. Rhein V., Song X., Wiesner A., Ittner L.M., Baysang G., Meier F., Ozmen L., Bluethmann H., Drose S., Brandt U., Savaskan E., Czech C., Gotz J., Eckert A. Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:20057-20062.
80. Beal M.F. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann. Neurol. 1995, 38:357-366.
81. DiMauro S., Schon E.A. Mitochondrial respiratory-chain diseases. N. Engl. J. Med. 2003, 348:2656-2668.
82. Mao P., Reddy P.H. Is multiple sclerosis a mitochondrial disease?. Biochim. Biophys. Acta 2010, 1802:66-79.
83. Reddy P.H. Mitochondrial oxidative damage in aging and Alzheimer's disease: implications for mitochondrially targeted antioxidant therapeutics. J. Biomed. Biotechnol. 2006, 2006:31372.
84. Droge W. Free radicals in the physiological control of cell function. Physiol. Rev. 2002, 82:47-95.
85. Valko M., Leibfritz D., Moncol J., Cronin M.T., Mazur M., Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol. 2007, 39:44-84.
86. Starkov A.A., Chinopoulos C., Fiskum G. Mitochondrial calcium and oxidative stress as mediators of ischemic brain injury. Cell Calcium 2004, 36:257-264.
87. Orrenius S. Reactive oxygen species in mitochondria-mediated cell death. Drug Metab. Rev. 2007, 39:443-455. R.H.
88. Swerdlow, Khan S.M. A 'mitochondrial cascade hypothesis' for sporadic Alzheimer's disease. Med. Hypotheses 2004, 63:8-20.
89. Leuner, Hauptmann S., Abdel-Kader R., Scherping I., Keil U., Strosznajder J.B., Eckert A., Muller W.E. Mitochondrial dysfunction: the first domino in brain aging and Alzheimer's disease?. Antioxid. Redox Signal. 2007, 9:1659-1675.
90. Gibson G.E., Starkov A., Blass J.P., Ratan R.R., Beal M.F. Cause and consequence: mitochondrial dysfunction initiates and propagates neuronal dysfunction, neuronal death and behavioral abnormalities in age-associated neurodegenerative diseases. Biochim. Biophys. Acta 2010, 1802:122-134.
91. Mancuso, Orsucci D., LoGerfo A., Calsolaro V., Siciliano G. Clinical features and pathogenesis of Alzheimer's disease: involvement of mitochondria and mitochondrial DNA. Adv. Exp. Med. Biol. 2010, 685:34-44.
92. Young K.J., Bennett J.P. The mitochondrial secret(ase) of Alzheimer's disease. J. Alzheimers Dis. 2010, 20(Suppl. 2):S381-S400.
93. Manczak, Anekonda T.S., Henson E., Park B.S., Quinn J., Reddy P.H. Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum. Mol. Genet. 2006, 15:1437-1449.
94. Caspersen C., Wang N., Yao J., Sosunov A., Chen X., Lustbader J.W., Xu H.W., Stern D., McKhann G., Yan S.D. Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. FASEB J. 2005, 19:2040-2041.
95. Devi L., Prabhu B.M., Galati D.F., Avadhani N.G., Anandatheerthavarada H.K. Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer's disease brain is associated with mitochondrial dysfunction. J. Neurosci. 2006, 26:9057-9068.
96. Crouch P.J., Blake R., Duce J.A., Ciccotosto G.D., Li Q.X., Barnham K.J., Curtain C.C., Cherny R.A., Cappai R., Dyrks T., Masters C.L., Trounce I.A. Copper-dependent inhibition of human cytochrome c oxidase by a dimeric conformer of amyloid-beta1-42. J. Neurosci. 2005, 25:672-679.
97. Lin M.T., Beal M.F. Alzheimer's APP mangles mitochondria. Nat. Med. 2006, 12:1241-1243.
98. Du H., Guo L., Fang F., Chen D., Sosunov A.A., McKhann G.M., Yan Y., Wang C., Zhang H., Molkentin J.D., Gunn-Moore F.J., Vonsattel J.P., Arancio O., Chen J.X., Yan S.D. Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease. Nat. Med. 2008, 14:1097-1105.
99. Pagani L., Eckert A. Amyloid-beta interaction with mitochondria. Int. J. Alzheimers Dis. 2011, 2011:925050.
100. Hansson Petersen C.A., Alikhani N., Behbahani H., Wiehager B., Pavlov P.F., Alafuzoff I., Leinonen V., Ito A., Winblad B., Glaser E., Ankarcrona M. The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:13145-13150.
101. Iijima-Ando K., Hearn S.A., Shenton C., Gatt A., Zhao L., Iijima K. Mitochondrial mislocalization underlies Abeta42-induced neuronal dysfunction in a Drosophila model of Alzheimer's disease. PLoS One 2009, 4:e8310.
102. Hensley K., Hall N., Subramaniam R., Cole P., Harris M., Aksenov M., Aksenova M., Gabbita S.P., Wu J.F., Carney J.M. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J. Neurochem. 1995, 65:2146-2156.
103. Halliwell B. Oxidative stress and neurodegeneration: where are we now?. J. Neurochem. 2006, 97:1634-1658.
104. Hensley K., Carney J.M., Mattson M.P., Aksenova M., Harris M., Wu J.F., Floyd R.A., Butterfield D.A. A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:3270-3274.
105. Behl C., Davis J.B., Lesley R., Schubert D. Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 1994, 77:817-827.
106. Varadarajan S., Yatin S., Aksenova M., Butterfield D.A. Review: Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity. J. Struct. Biol. 2000, 130:184-208.
107. Butterfield D.A. Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain. A review. Free Radic. Res. 2002, 36:1307-1313.
108. Aliev G., Seyidova D., Lamb B.T., Obrenovich M.E., Siedlak S.L., Vinters H.V., Friedland R.P., LaManna J.C., Smith M.A., Perry G. Mitochondria and vascular lesions as a central target for the development of Alzheimer's disease and Alzheimer disease-like pathology in transgenic mice. Neurol. Res. 2003, 25:665-674.
109. Shelat P.B., Chalimoniuk M., Wang J.H., Strosznajder J.B., Lee J.C., Sun A.Y., Simonyi A., Sun G.Y. Amyloid beta peptide and NMDA induce ROS from NADPH oxidase and AA release from cytosolic phospholipase A2 in cortical neurons. J. Neurochem. 2008, 106:45-55.
110. Vural H., Demirin H., Kara Y., Eren I., Delibas N. Alterations of plasma magnesium, copper, zinc, iron and selenium concentrations and some related erythrocyte antioxidant enzyme activities in patients with Alzheimer's disease. J. Trace Elem. Med. Biol. 2010, 24:169-173.
111. Lu J., Wang K., Rodova M., Esteves R., Berry D.E.L., Crafter A., Barrett M., Cardoso S.M., Onyango I., Parker W.D., Fontes J., Burns J.M., Swerdlow R.H. Polymorphic variation in cytochrome oxidase subunit genes. J. Alzheimers Dis. 2010, 21:141-154.
112. Mancuso, Calsolaro V., Orsucci D., Siciliano G., Murri L. Is there a primary role of the mitochondrial genome in Alzheimer's disease?. J. Bioenerg. Biomembr. 2009, 41:411-416.
113. Santoro A., Balbi V., Balducci E., Pirazzini C., Rosini F., Tavano F., Achilli A., Siviero P., Minicuci N., Bellavista E., Mishto M., Salvioli S., Marchegiani F., Cardelli M., Olivieri F., Nacmias B., Chiamenti A.M., Benussi L., Ghidoni R., Rose G., Gabelli C., Binetti G., Sorbi S., Crepaldi G., Passarino G., Torroni A., Franceschi C. Evidence for sub-haplogroup h5 of mitochondrial DNA as a risk factor for late onset Alzheimer's disease. PLoS One 2010, 5:e12037.
114. Aliyev A., Chen S.G., Seyidova D., Smith M.A., Perry G., de la Torre J., Aliev G. Mitochondria DNA deletions in atherosclerotic hypoperfused brain microvessels as a primary target for the development of Alzheimer's disease. J. Neurol. Sci. 2005, 285-292.
115. Murray I.V., Proza J.F., Sohrabji F., Lawler J.M. Vascular and metabolic dysfunction in Alzheimer's disease: a review. Exp. Biol. Med. (Maywood) 2011, 772-782.
116. Mancuso M., Coppede F., Murri L., Siciliano G. Mitochondrial cascade hypothesis of Alzheimer's disease: myth or reality?. Antioxid. Redox Signal. 2007, 9:1631-1646.
117. Calkins M.J., Reddy P.H. Amyloid beta impairs mitochondrial anterograde transport and degenerates synapses in Alzheimer's disease neurons. Biochim. Biophys. Acta 2011, 1812:507-513.
118. Lin C.J., Huang H.C., Jiang Z.F. Cu(II) interaction with amyloid-beta peptide: a review of neuroactive mechanisms in AD brains. Brain Res. Bull. 2010, 82:235-242.
119. Fukui H., Diaz F., Garcia S., Moraes C.T. Cytochrome c oxidase deficiency in neurons decreases both oxidative stress and amyloid formation in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:14163-14168.
120. Pickrell A.M., Fukui H., Moraes C.T. The role of cytochrome c oxidase deficiency in ROS and amyloid plaque formation. J. Bioenerg. Biomembr. 2009, 41:453-456.
121. Burguillos M.A., Deierborg T., Kavanagh E., Persson A., Hajji N., Garcia-Quintanilla A., Cano J., Brundin P., Englund E., Venero J.L., Joseph B. Caspase signalling controls microglia activation and neurotoxicity. Nature 2011, 472:319-324.
122. Cooke M.S., Olinski R., Evans M.D. Does measurement of oxidative damage to DNA have clinical significance?. Clin. Chim. Acta 2006, 365:30-49.
123. Miller S.A., Dykes D.D., Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988, 16:1215.
124. Wang L., Hirayasu K., Ishizawa M., Kobayashi Y. Purification of genomic DNA from human whole blood by isopropanol-fractionation with concentrated Nal and SDS. Nucleic Acids Res. 1994, 22:1774-1775.
125. Helbock H.J., Beckman K.B., Ames B.N. 8-Hydroxydeoxyguanosine and 8-hydroxyguanine as biomarkers of oxidative DNA damage. Methods Enzymol. 1999, 300:156-166.
126. Hamilton M.L., Van Remmen H., Drake J.A., Yang H., Guo Z.M., Kewitt K., Walter C.A., Richardson A. Does oxidative damage to DNA increase with age?. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:10469-10474.
127. Lau S.S., Peters M.M., Kleiner H.E., Canales P.L., Monks T.J. Linking the metabolism of hydroquinone to its nephrotoxicity and nephrocarcinogenicity. Adv. Exp. Med. Biol. 1996, 387:267-273.
128. Laws G.M., Adams S.P. Measurement of 8-OHdG in DNA by HPLC/ECD: the importance of DNA purity. Biotechniques 1996, 20:36-38.
129. Reddy P.H., McWeeney S., Park B.S., Manczak M., Gutala R.V., Partovi D., Jung Y., Yau V., Searles R., Mori M., Quinn J. Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer's disease. Hum. Mol. Genet. 2004, 13:1225-1240.
130. Manczak M., Park B.S., Jung Y., Reddy P.H. Differential expression of oxidative phosphorylation genes in patients with Alzheimer's disease: implications for early mitochondrial dysfunction and oxidative damage. Neuromolecular Med. 2004, 5:147-162.
131. Manczak M., Jung Y., Park B.S., Partovi D., Reddy P.H. Time-course of mitochondrial gene expressions in mice brains: implications for mitochondrial dysfunction, oxidative damage, and cytochrome c in aging. J. Neurochem. 2005, 92:494-504.
132. Shirendeb U., Reddy A.P., Manczak M., Calkins M.J., Mao P., Tagle D.A., Reddy P.H. Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage. Hum. Mol. Genet. 2011, 20:1438-1455.
133. Piperakis S.M., Visvardis E.E., Tassiou A.M. Comet assay for nuclear DNA damage. Methods Enzymol. 1999, 300:184-194.
134. Collins A.R. Investigating oxidative DNA damage and its repair using the comet assay. Mutat. Res. 2009, 681:24-32.
135. Collins A.R., Dobson V.L., Dusinska M., Kennedy G., Stetina R. The comet assay: what can it really tell us?. Mutat. Res. 1997, 375:183-193.
136. Suram A., Hegde M.L., Rao K.S. A new evidence for DNA nicking property of amyloid beta-peptide (1-42): relevance to Alzheimer's disease. Arch. Biochem. Biophys. 2007, 463:245-252.
137. Cimini, Moreno S., D'Amelio M., Cristiano L., D'Angelo B., Falone S., Benedetti E., Carrara P., Fanelli F., Cecconi F., Amicarelli F., Ceru M.P. Early biochemical and morphological modifications in the brain of a transgenic mouse model of Alzheimer's disease: a role for peroxisomes. J. Alzheimers Dis. 2009, 18:935-952.
138. Mecocci, MacGarvey U., Beal M.F. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann. Neurol. 1994, 36:747-751.
139. Lyras L., Cairns N.J., Jenner A., Jenner P., Halliwell B. An assessment of oxidative damage to proteins, lipids, and DNA in brain from patients with Alzheimer's disease. J. Neurochem. 1997, 68:2061-2069.
140. Gabbita S.P., Lovell M.A., Markesbery W.R. Increased nuclear DNA oxidation in the brain in Alzheimer's disease. J. Neurochem. 1998, 71:2034-2040.
141. Wang J., Xiong S., Xie C., Markesbery W.R., Lovell M.A. Increased oxidative damage in nuclear and mitochondrial DNA in Alzheimer's disease. J. Neurochem. 2005, 93:953-962.
142. Wang J., Markesbery W.R., Lovell M.A. Increased oxidative damage in nuclear and mitochondrial DNA in mild cognitive impairment. J. Neurochem. 2006, 96:825-832.
143. Chang S.W., Zhang D., Chung H.D., Zassenhaus H.P. The frequency of point mutations in mitochondrial DNA is elevated in the Alzheimer's brain. Biochem. Biophys. Res. Commun. 2000, 273:203-208.
144. Coskun P.E., Beal M.F., Wallace D.C. Alzheimer's brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:10726-10731.
145. Coskun P.E., Wyrembak J., Derbereva O., Melkonian G., Doran E., Lott I.T., Head E., Cotman C.W., Wallace D.C. Systemic mitochondrial dysfunction and the etiology of Alzheimer's disease and down syndrome dementia. J. Alzheimers Dis. 2010, 20(Suppl. 2):S293-S310.
146. Wadsworth T.L., Bishop J.A., Pappu A.S., Woltjer R.L., Quinn J.F. Evaluation of coenzyme Q as an antioxidant strategy for Alzheimer's disease. J. Alzheimers Dis. 2008, 14:225-234.
147. Manczak M., Mao P., Calkins M.J., Cornea A., Reddy A.P., Murphy M.P., Szeto H.H., Park B., Reddy P.H. Mitochondria-targeted antioxidants protect against amyloid-beta toxicity in Alzheimer's disease neurons. J. Alzheimers Dis. 2010, 20(Suppl. 2):S609-S631.
148. Van Raamsdonk J.M., Hekimi S. Reactive oxygen species and aging in Caenorhabditis elegans: causal or casual relationship?. Antioxid. Redox Signal. 2010, 13:1911-1953.
149. Ma T., Hoeffer C.A., Wong H., Massaad C.A., Zhou P., Iadecola C., Murphy M.P., Pautler R.G., Klann E. Amyloid beta-induced impairments in hippocampal synaptic plasticity are rescued by decreasing mitochondrial superoxide. J. Neurosci. 2011, 31:5589-5595.
150. Wollen K.A. Alzheimer's disease: the pros and cons of pharmaceutical, nutritional, botanical, and stimulatory therapies, with a discussion of treatment strategies from the perspective of patients and practitioners. Altern. Med. Rev. 2010, 15:223-244.
151. Zhang Z., Wang X., Chen Q., Shu L., Wang J., Shan G. Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial. Zhonghua Yi Xue Za Zhi 2002, 82:941-944.
152. Xu S.S., Gao Z.X., Weng Z., Du Z.M., Xu W.A., Yang J.S., Zhang M.L., Tong Z.H., Fang Y.S., Chai X.S. Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer's disease. Zhongguo Yao Li Xue Bao 1995, 16:391-395.
153. Rafii M.S., Walsh S., Little J.T., Behan K., Reynolds B., Ward C., Jin S., Thomas R., Aisen P.S. A phase II trial of huperzine A in mild to moderate Alzheimer disease. Neurology 2011, 76:1389-1394. Alzheimer's Disease Cooperative Study.
154. Li J., Wu H.M., Zhou R.L., Liu G.J., Dong B.R. Huperzine A for Alzheimer's disease. Cochrane Database Syst. Rev. 2008, (2):CD005592.
155. Wang B.S., Wang H., Wei Z.H., Song Y.Y., Zhang L., Chen H.Z. Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer's disease: an updated meta-analysis. J. Neural Transm. 2009, 116:457-465.
156. Desilets A.R., Gickas J.J., Dunican K.C. Role of huperzine a in the treatment of Alzheimer's disease. Ann. Pharmacother. 2009, 43:514-518.
157. Nagy Z., Esiri M.M., Smith A.D. The cell division cycle and the pathophysiology of Alzheimer's disease. Neuroscience 1998, 87:731-739.
158. Lu A.L., Li X., Gu Y., Wright P.M., Chang D.Y. Repair of oxidative DNA damage: mechanisms and functions. Cell Biochem. Biophys. 2001, 35:141-170.
159. Fishel M.L., Vasko M.R., Kelley M.R. DNA repair in neurons: so if they don't divide what's to repair?. Mutat. Res. 2007, 614:24-36.
160. de Souza-Pinto N.C., Hogue B.A., Bohr V.A. DNA repair and aging in mouse liver: 8-oxodG glycosylase activity increase in mitochondrial but not in nuclear extracts. Free Radic. Biol. Med. 2001, 30:916-923.
161. Jeppesen D.K., Bohr V.A., Stevnsner T. DNA repair deficiency in neurodegeneration. Prog. Neurobiol. 2011, 94:166-200.
162. Lovell M.A., Gabbita S.P., Markesbery W.R. Increased DNA oxidation and decreased levels of repair products in Alzheimer's disease ventricular CSF. J. Neurochem. 1999, 72:771-776.
163. Liu, Demple B. DNA repair in mammalian mitochondria: much more than we thought?. Environ. Mol. Mutagen. 2010, 51:417-426.
164. Yoshida Y., Izumi H., Ise T., Uramoto H., Torigoe T., Ishiguchi H., Murakami T., Tanabe M., Nakayama Y., Itoh H., Kasai H., Kohno K. Human mitochondrial transcription factor A binds preferentially to oxidatively damaged DNA. Biochem. Biophys. Res. Commun. 2002, 295:945-951.
165. Kang D., Hamasaki N. Mitochondrial transcription factor A in the maintenance of mitochondrial DNA: overview of its multiple roles. Ann. N. Y. Acad. Sci. 2005, 1042:101-108.
166. Canugovi, Maynard S., Bayne A.C., Sykora P., Tian J., de Souza-Pinto N.C., Croteau D.L., Bohr V.A. The mitochondrial transcription factor A functions in mitochondrial base excision repair. DNA Repair (Amst.) 2010, 9:1080-1089.
167. Yoshida Y., Izumi H., Torigoe T., Ishiguchi H., Itoh H., Kang D., Kohno K. P53 physically interacts with mitochondrial transcription factor A and differentially regulates binding to damaged DNA. Cancer Res. 2003, 63:3729-3734.
168. Wong T.S., Rajagopalan S., Townsley F.M., Freund S.M., Petrovich M., Loakes D., Fersht A.R. Physical and functional interactions between human mitochondrial single-stranded DNA-binding protein and tumour suppressor p53. Nucleic Acids Res. 2009, 37:568-581.
169. Boesch, Weber-Lotfi F., Ibrahim N., Tarasenko V., Cosset A., Paulus F., Lightowlers R.N., Dietrich A. DNA repair in organelles: pathways, organization, regulation, relevance in disease and aging. Biochim. Biophys. Acta 2011, 1813:186-200.
170. Karahalil, Hogue B.A., de Souza-Pinto N.C., Bohr V.A. Base excision repair capacity in mitochondria and nuclei: tissue-specific variations. FASEB J. 2002, 16:1895-1902.
171. Chen, Cao G., Hastings T., Feng Y., Pei W., O'Horo C., Chen J. Age-dependent decline of DNA repair activity for oxidative lesions in rat brain mitochondria. J. Neurochem. 2002, 81:1273-1284.
172. Gredilla, Garm C., Holm R., Bohr V.A., Stevnsner T. Differential age-related changes in mitochondrial DNA repair activities in mouse brain regions. Neurobiol. Aging 2010, 31:993-1002.
173. Imam S.Z., Karahalil B., Hogue B.A., Souza-Pinto N.C., Bohr V.A. Mitochondrial and nuclear DNA-repair capacity of various brain regions in mouse is altered in an age-dependent manner. Neurobiol. Aging 2006, 27:1129-1136.
174. Weissman L., Jo D.G., Sorensen M.M., de Souza-Pinto N.C., Markesbery W.R., Mattson M.P., Bohr V.A. Defective DNA base excision repair in brain from individuals with Alzheimer's disease and amnestic mild cognitive impairment. Nucleic Acids Res. 2007, 35:5545-5555.